The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Toll-like receptor 3, RIG-I-like receptors and the NLRP3 inflammasome: Key modulators of innate immune responses to double-stranded RNA viruses
Open accessAbstract
Double-stranded RNA (dsRNA), the genetic material for many RNA viruses, induces robust host immune responses via pattern recognition receptors, which include Toll-like receptor 3 (TLR3), retinoic acid-inducible gene-I-like receptors (RLRs) and the multi-protein NLRP3 inflammasome complex. The engagement of dsRNA receptors or inflammasome activation by viral dsRNA initiates complex intracellular signaling cascades that play essential roles in inflammation and innate immune responses, as well as the resultant development of adaptive immunity. This review focuses on signaling pathways mediated by TLR3, RLRs and the NLRP3 inflammasome, as well as the potential use of agonists and antagonists that target these pathways to treat disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Akira, S., & Takeda, K. (2004) · Nature reviews. Immunology · doi:10.1038/nri1391 · Cited by 8,312
Seth, R. B., Sun, L., Ea, C.-K., & Chen, Z. J. (2005) · Cell · doi:10.1016/j.cell.2005.08.012 · Cited by 3,329
Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
Cho, Y., Challa, S., Moquin, D., Genga, R., Ray, T. D., Guildford, M., & Chan, F. K.-M. (2009) · Cell · doi:10.1016/j.cell.2009.05.037 · Cited by 2,435 · cited 1×
“The RIP1–RIP3 complex has also been identified as a key regulator of programmed necrosis and viral-induced inflammation [30,31].”
BackgroundRIP3, an Energy Metabolism Regulator That Switches TNF-Induced Cell Death from Apoptosis to Necrosis
Zhang, D.-W., Shao, J., Lin, J., Zhang, N., Lu, B.-J., Lin, S.-C., Dong, M.-Q., & Han, J. (2009) · Science · doi:10.1126/science.1172308 · Cited by 1,931
Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898 · cited 1×
“by CD8+ T cells and serves as a link between innate and adaptive immunity [89].”
BackgroundFranchi, L., Eigenbrod, T., Muñoz-Planillo, R., & Nuñez, G. (2009) · Nature Immunology · doi:10.1038/ni.1703 · Cited by 1,834
Interleukin-1-receptor antagonist in type 2 diabetes mellitus
Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065213 · Cited by 1,798 · cited 1×
“A randomized clinical trial of anakinra in type 2 diabetes mellitus showed improvements in hyperglycemia, b-cell secretory function and systemic inflammation [111].”
BackgroundCell Type-Specific Involvement of RIG-I in Antiviral Response
Kato, H., Sato, S., Yoneyama, M., Yamamoto, M., Uematsu, S., Matsui, K., Tsujimura, T., Takeda, K., Fujita, T., Takeuchi, O., et al. (2005) · Immunity · doi:10.1016/j.immuni.2005.04.010 · Cited by 1,368
Allen, I. C., Scull, M. A., Moore, C. B., Holl, E. K., McElvania-TeKippe, E., Taxman, D. J., Guthrie, E. H., Pickles, R. J., & Ting, J. P.-Y. (2009) · Immunity · doi:10.1016/j.immuni.2009.02.005 · Cited by 1,113
Anti-inflammatory Agents: Present and Future
Dinarello, C. A. (2010) · Cell · doi:10.1016/j.cell.2010.02.043 · Cited by 1,095
mRNA is an endogenous ligand for toll-like receptor 3
Karikó, K., Ni, H., Capodici, J., Lamphier, M., & Weissman, D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310175200 · Cited by 1,062
IL-1 pathways in inflammation and human diseases
Gabay, C., Lamacchia, C., & Palmer, G. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.4 · Cited by 897
Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists
Kanzler, H., Barrat, F. J., Hessel, E. M., & Coffman, R. L. (2007) · Nature Medicine · doi:10.1038/nm1589 · Cited by 869 · cited 3×
“Poly(I:C) has been utilized as a therapeutic adjuvant in Phase II clinical trials of HIV vaccines and to induce Th1 and humoral immune responses to human papillomavirus in non-human primates [95,96].”
BackgroundMethodRIG-I detects viral genomic RNA during negative-strand RNA virus infection
Rehwinkel, J., Tan, C. P., Goubau, D., Schulz, O., Pichlmair, A., Bier, K., Robb, N., Vreede, F., Barclay, W., Fodor, E., et al. (2010) · Cell · doi:10.1016/j.cell.2010.01.020 · Cited by 585
Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes
Larsen, C. M., Faulenbach, M., Vaag, A., Ehses, J. A., Donath, M. Y., & Mandrup-Poulsen, T. (2009) · Diabetes Care · doi:10.2337/dc09-0533 · Cited by 401 · cited 1×
“improved 39 weeks after treatment withdrawal [112].”
5′-triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma
Poeck, H., Besch, R., Maihoefer, C., Renn, M., Tormo, D., Morskaya, S. S., Kirschnek, S., Gaffal, E., Landsberg, J., Hellmuth, J., et al. (2008) · Nature Medicine · doi:10.1038/nm.1887 · Cited by 387
Abulafia, D. P., de Rivero Vaccari, J. P., Lozano, J. D., Lotocki, G., Keane, R. W., & Dietrich, W. D. (2009) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2008.143 · Cited by 322 · cited 1×
“brain injury-associated inflammation [118].”
RIGorous Detection: Exposing Virus Through RNA Sensing
Rehwinkel, J., & Reis e Sousa, C. (2010) · Science · doi:10.1126/science.1185068 · Cited by 163 · cited 3×
“and the subsequent induction of type I IFNs [60].”
BackgroundInfluentialTrapp, S., Derby, N. R., Singer, R., Shaw, A., Williams, V. G., Turville, S. G., Bess, J. W., Lifson, J. D., & Robbiani, M. (2009) · Journal of Virology · doi:10.1128/jvi.00023-08 · Cited by 79
TLR3 agonists as immunotherapeutic agents
Nicodemus, C. F., & Berek, J. S. (2010) · Immunotherapy · doi:10.2217/imt.10.8 · Cited by 58 · cited 2×
“For example, poly(I:C) was developed in the 1960s as a synthetic inducer of type I interferon responses [94].”
Background
Cited by
The role of oxidative stress during inflammatory processes
Lugrin, J., Rosenblatt-Velin, N., Parapanov, R., & Liaudet, L. (2014) · Biological Chemistry · doi:10.1515/hsz-2013-0241 · Cited by 737
Comprehensive Identification of RNA-Binding Domains in Human Cells
Castello, A., Fischer, B., Frese, C. K., Horos, R., Alleaume, A.-M., Foehr, S., Curk, T., Krijgsveld, J., & Hentze, M. W. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.06.029 · Cited by 637
The RNA-binding proteomes from yeast to man harbour conserved enigmRBPs
Beckmann, B. M., Horos, R., Fischer, B., Castello, A., Eichelbaum, K., Alleaume, A.-M., Schwarzl, T., Curk, T., Foehr, S., Huber, W., et al. (2015) · Nature Communications · doi:10.1038/ncomms10127 · Cited by 468
TRAF molecules in cell signaling and in human diseases
Xie, P. (2013) · Journal of Molecular Signaling · doi:10.1186/1750-2187-8-7 · Cited by 466
Fung, G., Luo, H., Qiu, Y., Yang, D., & McManus, B. (2016) · Circulation Research · doi:10.1161/circresaha.115.306573 · Cited by 444
Metadata
- Authors
- Yu, M., & Levine, S. J.
- Venue
- Cytokine & Growth Factor Reviews
- Publisher
- Elsevier BV
- Published
- 2011-04
- Volume
- 22
- Issue
- 2
- Pages
- 63-72
- ISSN
- 1359-6101 (ISSN-L)
- OpenAlex
- W1965869838
- Cited by
- 190
- References
- 21
- FWCI
- 0.88
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.